Search
01/01/2022
El anciano frágil en urgencias: principales retos
Puig-Campmany M., Ris-Romeu J.. El anciano frágil en urgencias: principales retos. EMERGENCIAS. 2022; 34(6)DOI:. PMID:36625690. IF:5.500(Q1/2D).
01/01/2026
Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey
Cabrera-Martín, MN, Aguiar-Fernández, P, Camacho-Martí, V, Guillén-Valderrama, EF, Jiménez-Bonilla, JF, Lojo-Ramírez, JA, López-Mora, DA, Matías-Guiu, JA, Paredes-Rodríguez, P, Perissinotti, A, Arbizu, J. Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey. Journal Of Alzheimers Disease Reports. 2026; 10DOI:10.1177/25424823261437129. PMID:. IF:(Q/D).
01/03/2024
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2024; 25(2)DOI:10.1007/s40257-023-00816-1. PMID:37804472. IF:8.800(Q1/1D).
01/02/2024
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Reich, K, Bianchi, L, Khemis, A, Maul, JT, Tsianakas, A, Schempp, CM, Petersen, K, Noergaard, MM, Puig, L. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and Therapy. 2024; 14(2)DOI:10.1007/s13555-023-01092-x. PMID:38300408. IF:4.200(Q1/1D).